A Semi-Automated, Non-Radioactive Assay for the Detection of Antibody-Based Complement-Dependent Cytotoxicity

Pharmaceutical companies are increasingly focused on biologic therapeutics rather than biochemical, chemical and radiological compounds for many cancer treatments. Biologic therapeutics only target and destroy specific cancer cells, thus preventing damage to surrounding, healthy cells and reducing unwanted cytotoxic events. In this application note read about the use of a non-radioactive, bioluminescent antibody-based Complement-Dependent Cytotoxicity (CDC) assay.